Clinical Trial Update: Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU [Phase 3]

View source ↗

Summary

Phase 3 study evaluating USL261 for epilepsy has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• USL261

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2018-11-27